The practical utility of amyloid and FDG-PET in an academic dementia center

[1]  P. Scheltens,et al.  Impact of molecular imaging on the diagnostic process in a memory clinic , 2013, Alzheimer's & Dementia.

[2]  Colin L. Masters,et al.  Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-Amyloid Imaging in Aging and Dementia , 2013, The Journal of Nuclear Medicine.

[3]  Keith A. Johnson,et al.  Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association , 2013, The Journal of Nuclear Medicine.

[4]  Cindee M. Madison,et al.  Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. , 2013, Brain : a journal of neurology.

[5]  Murray Grossman,et al.  Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet Neurology.

[6]  Peter Herscovitch,et al.  Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association , 2013, Alzheimer's & Dementia.

[7]  M. Mintun,et al.  Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline , 2013, Alzheimer disease and associated disorders.

[8]  M. Mintun,et al.  Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.

[9]  G. Waldemar,et al.  Added Diagnostic Value of 11C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis , 2012, Dementia and Geriatric Cognitive Disorders Extra.

[10]  Lucie Yang,et al.  Brain amyloid imaging--FDA approval of florbetapir F18 injection. , 2012, The New England journal of medicine.

[11]  M. Mendez,et al.  Nonamnestic Presentations of Early-Onset Alzheimer’s Disease , 2012, American journal of Alzheimer's disease and other dementias.

[12]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[13]  M. Blankenburg,et al.  Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.

[14]  C. Rowe,et al.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  J. Kornak,et al.  Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .

[16]  G. Rabinovici,et al.  Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications , 2011, Alzheimer's Research & Therapy.

[17]  J. Trojanowski,et al.  Clinicopathological correlations in corticobasal degeneration , 2011, Annals of neurology.

[18]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[19]  G. Rabinovici,et al.  Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution , 2011, Neurology.

[20]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[21]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[22]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[23]  J. Neuhaus,et al.  Off-Label Medication Use in Frontotemporal Dementia , 2010, American journal of Alzheimer's disease and other dementias.

[24]  M. Weiner,et al.  Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. , 2010, Brain : a journal of neurology.

[25]  John Q. Trojanowski,et al.  Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update , 2009, Acta Neuropathologica.

[26]  W. Jagust,et al.  Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia , 2008, Annals of neurology.

[27]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[28]  V. Libri,et al.  PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. , 2007, Brain : a journal of neurology.

[29]  Andrew Kertesz,et al.  The cognitive profile of posterior cortical atrophy , 2006, Neurology.

[30]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[31]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[32]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[33]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[34]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[35]  M. Freedman,et al.  Frontotemporal lobar degeneration , 1998, Neurology.

[36]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[37]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[38]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[39]  E. Huang,et al.  Nonfluent/Agrammatic PPA with In-Vivo Cortical Amyloidosis and Pick’s Disease Pathology , 2013, Behavioural neurology.

[40]  D. Bennett,et al.  The neuropathology of older persons with and without dementia from community versus clinic cohorts. , 2009, Journal of Alzheimer's disease : JAD.

[41]  Maria Luisa Gorno-Tempini,et al.  Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. , 2006, Archives of neurology.